Last reviewed · How we verify
Treatment E
Treatment E's mechanism is not specified in the provided information.
At a glance
| Generic name | Treatment E |
|---|---|
| Also known as | simeprevir |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Without additional details about Treatment E's molecular target or pharmacological action, a mechanistic description cannot be accurately provided. Further information from clinical trial data or product labeling would be required.
Approved indications
Common side effects
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies (PHASE2)
- Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma (PHASE1, PHASE2)
- Impact of a Mindfulness Intervention on Infertile Women Undergoing Assisted Reproductive Technique Treatments (NA)
- Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment E CI brief — competitive landscape report
- Treatment E updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI